Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 27, 2026, 5:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,157 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Inflammation; Skin Clear all
Completed Not applicable Interventional Accepts healthy volunteers

ASAP: Access to Syringes at Pharmacies for the Prevention of Bloodborne Infections Among People Who Inject Drugs

NCT05270135
View directory record Official record
Conditions
Skin and Soft Tissue Infections, Hiv, Hepatitis C, Bloodstream Infection
Interventions
ASAP
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Jun 27, 2026, 5:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Evaluate Pharmacokinetics, Immunogenicity, Safety, and Tolerability of LEO 138559 in Healthy Japanese Subjects

NCT05099133
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
LEO 138559, LEO 138559 Placebo
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Jun 27, 2026, 5:21 AM EDT
Recruiting Phase 2 Interventional

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

NCT06947993
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
GHZ339, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
22
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Fountain Valley, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Jun 27, 2026, 5:21 AM EDT
Completed Not applicable Interventional Results available

Psoriasis Inflammation and Systemic Co Morbidities

NCT01170715
View directory record Official record
Conditions
Psoriasis
Interventions
Etanercept
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 7, 2021 · Synced Jun 27, 2026, 5:21 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Evaluation of Topical B12 for the Treatment of Childhood Atopic Dermatitis

NCT00465699
View directory record Official record
Conditions
Eczema
Interventions
Topical B12 0.07%
Drug
Lead sponsor
Spartanburg Regional Healthcare System
Other
Eligibility
6 Months to 18 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 24, 2007 · Synced Jun 27, 2026, 5:21 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation

NCT05535738
View directory record Official record
Conditions
Skin Inflammation, Allergic Contact Dermatitis
Interventions
Squaric Acid Dibutyl Ester, Known patch test allergens, Dupilumab, Adalimumab, Ustekinumab, Guselkumab, Canakinumab, Sarilumab, Triamcinolone Acetonide, Betamethasone Valerate, Fluticasone Propionate, Microneedle, Suction blistering, Skin punch biopsy
Drug · Other · Device + 1 more
Lead sponsor
Wei-Che Ko
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jun 27, 2026, 5:21 AM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)

NCT06018428
View directory record Official record
Conditions
Alopecia Areata
Interventions
bempikibart (ADX-914)
Drug
Lead sponsor
Q32 Bio Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
28
States / cities
Scottsdale, Arizona • Fayetteville, Arkansas • Hot Springs, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jun 27, 2026, 5:21 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effects of White Button Mushroom on Inflammation in Obese Postmenopausal Women at High Risk of Breast Cancer

NCT04913064
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Questionnaire Administration, White Button Mushroom Extract
Other · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
21 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jan 4, 2026 · Synced Jun 27, 2026, 5:21 AM EDT
Completed Phase 1 Interventional

A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis

NCT01702181
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
OPA-15406, Tacrolimus, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
12
States / cities
Mobile, Alabama • Hot Springs, Arizona • Irvine, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2014 · Synced Jun 27, 2026, 5:21 AM EDT
Completed Phase 3 Interventional Results available

A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis

NCT03435081
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Baricitinib, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
60
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Beverly Hills, California + 52 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2022 · Synced Jun 27, 2026, 5:21 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis

NCT04018027
View directory record Official record
Conditions
Pruritus, Atopic Dermatitis
Interventions
difelikefalin 0.25 mg, difelikefalin 0.5 mg, difelikefalin 1.0 mg, Placebo
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
38
States / cities
Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Jun 27, 2026, 5:21 AM EDT
Completed Not applicable Interventional

High Intensity Interval Training and Rheumatoid Arthritis

NCT02528344
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
HIIT
Behavioral
Lead sponsor
Duke University
Other
Eligibility
60 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Jun 27, 2026, 5:21 AM EDT
Completed Phase 2 Interventional

Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Pruritus Associated With Atopic Dermatitis

NCT02475447
View directory record Official record
Conditions
Pruritus, Atopic Dermatitis
Interventions
Asimadoline, Placebo
Drug
Lead sponsor
Tioga Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • North Miami Beach, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Jun 27, 2026, 5:21 AM EDT
Completed Phase 1 Interventional

Eucrisa for Atopic Dermatitis

NCT03250663
View directory record Official record
Conditions
Mild to Moderate Atopic Dermatitis
Interventions
Online Treatment response, EUCRISA
Behavioral · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
2 Years to 64 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Jun 27, 2026, 5:21 AM EDT
Completed Phase 2 Interventional Results available

Preventative Skin Care for Children Undergoing Targeted CNS Tumor Therapy

NCT04479514
View directory record Official record
Conditions
Pediatric Cancer, CNS Tumor, Childhood, Skin Inflammation
Interventions
Warm Baths or Showers, Moisturizer, SPF 30 or Higher Suncreen, Sun Protective Clothing, Limited Sun Exposure, Dilute bleach baths
Other · Drug · Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
6 Months to 18 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jun 27, 2026, 5:21 AM EDT
Recruiting Phase 2 Interventional

Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

NCT05892614
View directory record Official record
Conditions
Interstitial Lung Disease
Interventions
efzofitimod 450 mg, efzofitimod 270 mg, Placebo
Drug
Lead sponsor
aTyr Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
15
States / cities
Los Angeles, California • San Diego, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Jun 27, 2026, 5:21 AM EDT
Completed Phase 4 Interventional Results available

Adherence to Topical Hydrocortisone 17-butyrate 0.1% (Locoid®) Using Different Vehicles in Adults With Atopic Dermatitis

NCT00693693
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
hydrocortisone 17-butyrate 0.1% Cream preparation, hydrocortisone 17-butyrate 0.1% Ointment preparation, hydrocortisone 17-butyrate 0.1% Lipocream preparation
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 9, 2018 · Synced Jun 27, 2026, 5:21 AM EDT
Completed Phase 2 Interventional Results available

A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.

NCT05375955
View directory record Official record
Conditions
Atopic Dermatitis, Plaque Psoriasis
Interventions
PF-07038124 ointment 0.01%, Vehicle ointment, PF-07038124 ointment 0.03%, PF-07038124 ointment 0.06%
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
23
States / cities
Encinitas, California • Los Angeles, California • Cape Coral, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Jun 27, 2026, 5:21 AM EDT
Terminated Phase 2 Interventional Results available

An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis

NCT05399368
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
RPT193, Placebo
Drug · Other
Lead sponsor
RAPT Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
56
States / cities
Birmingham, Alabama • Scottsdale, Arizona • North Little Rock, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Jun 27, 2026, 5:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Skin Barrier Biophysical Properties and Clinical Appearance After Moisturizer in Dry Skin

NCT03093597
View directory record Official record
Conditions
Xerosis, Xerosis Cutis, Dry Skin; Eczema
Interventions
virgin coconut oil, virgin jojoba oil, virgin almond oil, white petrolatum ointment
Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Tucson, Arizona • Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Jun 27, 2026, 5:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study

NCT01737710
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Fluzone® Intradermal Vaccine, Fluzone® (Intramuscular) vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years · Female only
Enrollment
368 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
5
States / cities
Denver, Colorado • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Jun 27, 2026, 5:21 AM EDT
Terminated Not applicable Interventional

Point-of-Care Ultrasound Educational Initiative for Insect Bites

NCT03619746
View directory record Official record
Conditions
Cellulitis, Insect Bites, Insect Stings
Interventions
POCUS Educational Intervention
Behavioral
Lead sponsor
New York City Health and Hospitals Corporation
Other
Eligibility
3 Months to 20 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Jun 27, 2026, 5:21 AM EDT
Recruiting Phase 1 Interventional

A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis

NCT06055361
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
BxC-I17e (primed iMSC derived Extracellular vesicles(EV)), Placebo
Drug
Lead sponsor
Brexogen Inc.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
North Little Rock, Arkansas • Camp Hill, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Jun 27, 2026, 5:21 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections

NCT02052388
View directory record Official record
Conditions
Skin Infection, Bacterial Infection
Interventions
Daptomycin, Brilacidin
Drug
Lead sponsor
Cellceutix Corporation
Industry
Eligibility
18 Years to 85 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
4
States / cities
Chula Vista, California • La Mesa, California • Oceanside, California + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Jun 27, 2026, 5:21 AM EDT